This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Will Core MedSurg Segment Drive Stryker's (SYK) Q2 Earnings?
by Zacks Equity Research
Solid segmental performances at Medsurg, Orthopaedic and Neurotechnology & Spine and an upbeat second quarter 2019 view are likely to fuel Stryker's (SYK) Q2 earnings. However, forex might be a woe.
Will LabCorp's (LH) Q2 Earnings Gain From Overall Growth?
by Zacks Equity Research
Within Covance Drug Development, LabCorp (LH) is focused on driving profitable growth through expanded solutions and enhanced operational capabilities.
Baxter (BAX) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Baxter (BAX) expects second-quarter revenues to decline 2% on a reported basis.
Analytical Instruments to Aid Thermo Fisher (TMO) Q2 Earnings?
by Zacks Equity Research
Solid global demand, substantial impact from the electron microscopy business and robust volume growth and productivity are likely to favor Thermo Fisher's (TMO) analytical instruments revenues.
What's in the Offing for Cerner's (CERN) Earnings in Q2?
by Zacks Equity Research
Top-line growth and solid show by Population Health, Revenue Cycle and IT Works are likely to aid Cerner's (CERN) Q2 earnings. However, expected decline in bookings is likely to be a dampener.
What's in Store for Varian Medical (VAR) in Q3 Earnings?
by Zacks Equity Research
Probable revenue growth in APAC and EMEA regions and higher Oncology revenues are likely to aid Varian Medical (VAR) in Q3 earnings. However, contraction in margins might be a dampener.
What's in Store for Align Technology (ALGN) in Q2 Earnings?
by Zacks Equity Research
Align Technology (ALGN) is expected to deliver a strong second quarter on continued adoption of Invisalign system.
Intuitive Surgical (ISRG) Q2 Earnings Beat, Guidance Narrowed
by Zacks Equity Research
Intuitive Surgical (ISRG) expects 2019 procedure growth within 16-17%.
Will 2-Pronged Plan Aid Quest Diagnostics (DGX) Q2 Earnings?
by Zacks Equity Research
Quest Diagnostics' (DGX) frequent partnership wins with health care leaders and sensible buyouts are creating bountiful opportunities for the top and the bottom line.
BioTelemetry (BEAT) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
BioTelemetry's (BEAT) strong second-quarter 2019 expectations are indicative of solid results.
What's in Store for Edwards Lifesciences' (EW) Q2 Earnings?
by Zacks Equity Research
Edwards Lifesciences (EW) is likely to deliver a solid second quarter on robust segmental performance.
Here's Why Investors Should Consider Cerner (CERN) Stock
by Zacks Equity Research
For the second quarter, Cerner (CERN) expects revenues between $1.41 billion and $1.46 billion.
Falling Earnings Estimates Signal Weakness Ahead for Patterson Companies (PDCO)
by Zacks Equity Research
Patterson Companies (PDCO) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.
7 S&P 500-Beating Stocks to Buy Ahead of Q2 Earnings
by Aniruddha Ganguly
Here we pick seven stocks that have outperformed the S&P 500 and are likely to beat earnings estimates this reporting cycle.
Can Global Industrial Unit Drive Ecolab's (ECL) Q2 Earnings?
by Zacks Equity Research
Ecolab (ECL) likely to see impressive growth in second-quarter adjusted earnings per share.
Will Abbott's (ABT) Q2 Earnings Gain From Overall Growth?
by Zacks Equity Research
Abbott's (ABT) consistent rise on a strong Diabetes Care business performance is seen over the last few quarters.
McKesson (MCK) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Top-line growth and better-than-expected segmental performance are likely to aid McKesson (MCK) in Q1. However, rise in adjusted operating expenses is likely to be a dampener.
Can Instruments Drive Intuitive Surgical (ISRG) Q2 Earnings?
by Zacks Equity Research
Intuitive Surgical (ISRG) expects its core Instruments and Accessories unit to boost second-quarter 2019 results.
AngioDynamics (ANGO) Q4 Earnings Miss, Revenues Top Estimates
by Zacks Equity Research
AngioDyamics (ANGO) gains from solid segmental contributions in fourth-quarter fiscal 2019.
Smith & Nephew Acquires Atracsys, Expands Robotic Portfolio
by Zacks Equity Research
With Smith & Nephew's (SNN) buyout of Atracsys, the latter's fusionTrack 500 optical tracking camera will be a core enabling technology for the company's next-generation robotics platform.
Varian to Acquire Boston Scientific's Embolic Bead Products
by Zacks Equity Research
Varian (VAR) expects the buyout to prove accretive to its fiscal 2020 reported and adjusted earnings per share.
Myriad Genetics' Elevate 2020 Plan Holds Promise Amid Issues
by Zacks Equity Research
Myriad Genetics (MYGN) unveils an 'Elevate 2020' program that aims to generate $50 million in incremental operating income by fiscal 2020.
Medtronic's Titan Spine Buyout to Boost Spine Surgery Range
by Zacks Equity Research
Medtronic's (MDT) comprehensive biologics portfolio clubbed with Titan Spine's surface-enhanced titanium implants can enhance patient outcomes in spinal procedures.
Walgreens Gains on Strategic Deals, Margin Pressure Remains
by Zacks Equity Research
Walgreens Boots' (WBA) Retail Pharmacy USA division is witnessing comparable prescription growth and also benefiting from a strong retail prescription market.
Thermo Fisher's Unit Sale May Not Ail Specialty Diagnostics
by Zacks Equity Research
The Anatomical Pathology business of Thermo Fisher (TMO) belongs to its Specialty Diagnostics segment that serves customers across healthcare and clinical laboratories.